Overview
Tom Bosschaerts is Chief Operating Officer of ImmuneWatch, a company he co-founded in September 2021 and where he took up his current role in January 2026. He had previously served as its Director of Operations from April 2023.
Based in Lier, Bosschaerts held a series of valorisation manager posts at the University of Antwerp between June 2018 and April 2023, covering life sciences, the PreMeT programme, and infectious diseases and environmental health. Before that he was project and grant manager at eTheRNA, senior project manager life sciences at CMAST from 2014 to 2018, and project manager global public health at The Janssen Pharmaceutical Companies of Johnson & Johnson. Earlier in his career he was R&D manager at Dafra Pharma and a medical and scientific writer at Archemin.
He studied bio-science engineering at the Vrije Universiteit Brussel, graduating in 2005, and went on to complete a PhD in immunology and infectious diseases there in 2010. He attended Atheneum Lier from 1996 to 2000.
Career history
In the news
- Last chance to submit to our TCR grant program, let us know your project idea before Oct 30!
- Earlier this year Samuel Rulli, Jr., Tom Bosschaerts and myself where chatting on how ImmuneWatch and QIAGEN could collaborate a bit more intensively. How do we show the value of TCR sequencing + clustering & specificity analysis to those running clinical trials in oncology and autoimmunity? "Maybe a grant? Free sequencing and free analysis both for academia and industry" I think that we were all pretty quickly aligned as soon as someone said that. And so we went to work: - Wrote grant outline - Grant rules and how we would
- Last chance to have a chat with us here at The World Vaccine Congress Europe in Amsterdam But please no coffee anymore, we've had our shots for the day😄☕ Tom Bosschaerts
- Throwback to last year at the World Vaccine Conference in Amsterdam. We'll be there again next week, time flies! Looking forward to seeing some familiar faces again but also to meet new people. If you are also going to be around, let's have a chat!
- Hey but have you checked whether any of these TCRs matches with a known TCR in the public space?" If you ever had this question and: - Needed 30+ minutes to find an answer to it - Had to ask a colleague because you needed some coding to get an answer - Were confused with the statistics reported to you (is this a match or something I can ignore?) Then check out our solution ImmuneWatch DETECT. You can smoothly integrate it in Claude or ChatGPT and just ask it to do the work for you. It takes less than 5 minutes and you are sure
- Analysing T cell responses against infectious disease antigens is where it all started for ImmuneWatch. Today, monitoring efficacy of vaccination is still an important use case of our technology, and 50% of our training database is made up of viral antigens. Identifying and tracking virus-specific TCRs goes beyond application in infectious disease vaccination, as viruses (such as EBV, HHV, CMV, HPV, ...) are implicated in a range of diseases, from autoimmunity and oncology to transplantation monitoring. We have a new webinar
- Why is TCR-epitope prediction so much better validated for viruses than for cancer?" is a question worth answering properly. Viral epitopes are shared across patients, so you can generate TCR-epitope training data on them at scale. CMV, EBV, SARS-CoV-2, all well covered. Tumor neoantigens are private to each patient, so the reference data is much thinner. That's exactly why infectious disease and vaccine monitoring is a strong place to apply epitope-specific T-cell annotation right now. On 30 September we're running a
- We teamed up with QIAGEN for a joint grant program on TCR sequencing! Grant winners get free TCR sequencing and in-depth TCR data analysis in service. Check out our website for more information, or register for our webinar with QIAGEN tomorrow to learn more about this opportunity. https://lnkd.in/eNUBxi2x
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.